Perspective Therapeutics (NYSE:CATX) Receives Outperform Rating from Wedbush

Wedbush reaffirmed their outperform rating on shares of Perspective Therapeutics (NYSE:CATX) in a research note released on Thursday,RTT News reports. They currently have a $11.00 price target on the stock.

A number of other brokerages have also recently issued reports on CATX. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Perspective Therapeutics in a research note on Friday, September 19th. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Saturday, July 12th. Finally, B. Riley reiterated a “buy” rating and issued a $12.00 price target (up previously from $9.00) on shares of Perspective Therapeutics in a research note on Monday, June 23rd. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Perspective Therapeutics currently has an average rating of “Buy” and an average target price of $12.56.

Perspective Therapeutics Trading Up 1.7%

Shares of Perspective Therapeutics stock opened at $3.49 on Thursday. The firm’s 50-day moving average is $3.54 and its 200 day moving average is $3.07. Perspective Therapeutics has a 1 year low of $1.60 and a 1 year high of $13.56.

Institutional Investors Weigh In On Perspective Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the stock. Taylor & Morgan Wealth Management LLC grew its holdings in Perspective Therapeutics by 4.4% during the 2nd quarter. Taylor & Morgan Wealth Management LLC now owns 94,000 shares of the company’s stock valued at $323,000 after buying an additional 4,000 shares in the last quarter. Nicholson Wealth Management Group LLC grew its holdings in Perspective Therapeutics by 0.3% during the 2nd quarter. Nicholson Wealth Management Group LLC now owns 1,614,283 shares of the company’s stock valued at $5,553,000 after buying an additional 5,000 shares in the last quarter. ProShare Advisors LLC grew its holdings in Perspective Therapeutics by 49.1% during the 4th quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock valued at $49,000 after buying an additional 5,011 shares in the last quarter. MetLife Investment Management LLC boosted its position in shares of Perspective Therapeutics by 40.9% during the 1st quarter. MetLife Investment Management LLC now owns 31,310 shares of the company’s stock valued at $67,000 after acquiring an additional 9,082 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Perspective Therapeutics by 19.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,150 shares of the company’s stock valued at $224,000 after acquiring an additional 11,472 shares during the last quarter. 54.66% of the stock is owned by hedge funds and other institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.